Bioinformatics Partnering Terms and Agreements

  • September 2013
  • -
  • Currentpartnering
  • -
  • 1268 pages

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in bioinformatics partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for bioinformatics

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.

Bioinformatics is the application of computer science and information technology to the field of biology and medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificial intelligence, information and computation theory, software engineering, data mining, image processing, modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generating new knowledge of biology and medicine.

Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2007, including financial terms where available, including over 1700 links to online deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading bioinformatics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z , deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.

Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of bioinformatics deal trends since 2007
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of bioinformatics agreements with numerous real life case studies
•Comprehensive access to over 1700 bioinformatics deals entered into by the world’s biopharma companies
• Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a bioinformatics agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Bioinformatics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to bioinformatics trends and structure of deals entered into by leading companies worldwide.

Bioinformatics Partnering Terms and Agreements includes:
o Trends in bioinformatics dealmaking in the biopharma industry since 2007
o Analysis of bioinformatics deal structure
o Access to headline, upfront, milestone and royalty data
o Case studies of real-life bioinformatics deals
o Access to over 1700 bioinformatics deal documents
o Access to contract documents where available
o The leading bioinformatics deals by value since 2007
o Most active bioinformatics dealmakers since 2007
o The leading bioinformatics partnering resources In Bioinformatics Partnering Terms and Agreements, the available contracts are listed by:
o Company A-Z
o Headline value
o Stage of development at signing
o Deal component type
o Therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Bioinformatics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 bioinformatics deals.

Analyzing actual contract agreements allows assessment of the following:
o What are the precise bioinformatics rights granted or optioned?
o What is actually granted by the agreement to the partner company?
o What exclusivity is granted?
o What is the payment structure for the deal?
o How are sales and payments audited?
o What is the deal term?
o How are the key terms of the agreement defined?
o How are IPRs handled and owned?
o Who is responsible for commercialization?
o Who is responsible for development, supply, and manufacture?
o How is confidentiality and publication managed? o How are disputes to be resolved?
o Under what conditions can the deal be terminated? o What happens when there is a change of ownership?
o What sublicensing and subcontracting provisions have been agreed? o Which boilerplate clauses does the company insist upon?
o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
o Which jurisdiction does the company insist upon for agreement law?

Number of pages: The report consists of 1268 pages (including appendices)

Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of bioinformatics deal trends since 2007
Access to headline, upfront, milestone and royalty data
Analysis of the structure of bioinformatics agreements with numerous real life case studies
Comprehensive access to over 1700 bioinformatics deal documents entered into by the world’s biopharma companies
Detailed access to actual bioinformatics contracts
Provides insight into deals dentered by top 50 big pharma and top big biotech companies
Insight into the terms included in a bioinformatics agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies
Insight into the terms included in a bioinformatics agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in bioinformatics dealmaking

2.1. Introduction
2.2. Bioinformatics partnering over the years
2.3. Big pharma bioinformatics dealmaking activity
2.4. Big Biotech bioinformatics dealmaking activity
2.5. Most active bioinformatics dealmakers
2.6. Bioinformatics partnering by deal type
2.7. Bioinformatics partnering by stage of development
2.8. Bioinformatics partnering by disease type
2.9. Average deal terms for bioinformatics partnering
2.9.1 Bioinformatics partnering headline values
2.9.2 Bioinformatics deal upfront payments
2.9.3 Bioinformatics deal milestone payments
2.9.4 Bioinformatics royalty rates

Chapter 3 - Leading bioinformatics deals

3.1. Introduction
3.2. Top bioinformatics deals by value
3.3. Top bioinformatics deals involving big pharma

Chapter 4 - Bigpharma bioinformatics deals

4.1. Introduction
4.2. How to use bigpharma bioinformatics partnering deals
4.3. Big pharma bioinformatics partnering company profiles
Abbott
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Galderma
GlaxoSmithKline
Grifols
Hospira
Johnson and Johnson
Lundbeck
Merck and Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shire
Takeda
Teva
UCB
Valeant

Chapter 5 - Bigbiotech bioinformatics deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech bioinformatics partnering company profiles
Array Biopharma
Dendreon
Elan
Galapagos
Genmab
Grifols
Ipsen
Novo Nordisk
Onyx Pharmaceuticals
Spectrum Pharmaceuticals
Vertex Pharmaceuticals

Chapter 6 - Bioinformatics dealmaking directory with contracts

6.1. Introduction
6.2. By stage of development
Discovery
Formulation
Marketed
Phase III
6.3. By deal type
Asset purchase
Bigpharma outlicensing
Collaborative RandD
Co-market
Contract service
Co-promotion
Development
Distribution
Equity purchase
Licensing
Litigation
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Sub-license
Supply
Termination
6.4. By therapy area
Cardiovascular
Hematology
Hospital care
Infectives
Oncology

Chapter 7 - Bioinformatics dealmaking by technology type
Bioinformatics
Software tools

Chapter 8 - Partnering resource center
8.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports


Appendices

Appendix 1: By company A-Z
Appendix 2: By stage of development
Appendix 3: By deal type
Appendix 4: By therapy area




Table of figures


Figure 1: Bioinformatics partnering since 2007
Figure 2: Big pharma - top 50 - bioinformatics deals 2007 to 2013
Figure 3: Big pharma biomarker deal frequency - 2007 to 2013
Figure 4: Big biotech - top 50 - bioinformatics deals 2007 to 2013
Figure 5: Big biotech biomarker deal frequency - 2007 to 2013
Figure 6: Active bioinformatics dealmaking activity- 2007 to 2013
Figure 4: Bioinformatics partnering by deal type since 2007
Figure 5: Bioinformatics partnering by deal type since 2007
Figure 6: Bioinformatics partnering by disease type since 2007
Figure 10: Bioinformatics deals with a headline value - by stage of development
Figure 11: Bioinformatics deal headline value distribution - discovery stage, US$million
Figure 12: Bioinformatics deal headline value distribution - preclinical stage, US$million
Figure 13: Bioinformatics deal headline value distribution - phase I stage, US$million
Figure 14: Bioinformatics deal headline value distribution - phase II stage, US$million
Figure 15: Bioinformatics deal headline value distribution - phase III stage, US$million
Figure 16: Bioinformatics deal headline value distribution - regulatory stage, US$million
Figure 17: Bioinformatics deal headline value distribution - marketed stage, US$million
Figure 18: Summary median headline value by stage of development, 2007-2013
Figure 19: Bioinformatics deals with upfront payment values - by stage of development
Figure 20: Bioinformatics deal upfront payment distribution - discovery stage, US$million
Figure 21: Bioinformatics deal upfront payment distribution - preclinical stage, US$million
Figure 22: Bioinformatics deal upfront payment distribution - phase I stage, US$million
Figure 23: Bioinformatics deal upfront payment distribution - phase II stage, US$million
Figure 24: Bioinformatics deal upfront payment distribution - phase III stage, US$million
Figure 25: Bioinformatics deal upfront payment distribution - regulatory stage, US$million
Figure 26: Bioinformatics deal upfront payment distribution - phase marketed stage, US$million
Figure 27: Summary median upfront value by stage of development, 2007-2013
Figure 28: Bioinformatics deals with milestone payments - by stage of development
Figure 29: Bioinformatics deal milestone value distribution, US$million - discovery stage
Figure 30: Bioinformatics deal milestone value distribution, US$million - preclinical stage
Figure 31: Bioinformatics deal milestone value distribution, US$million - phase I stage
Figure 32: Bioinformatics deal milestone value distribution, US$million - phase II stage
Figure 33: Bioinformatics deal milestone value distribution, US$million - phase III stage
Figure 34: Bioinformatics deal milestone value distribution, US$million - regulatory stage
Figure 35: Bioinformatics deal milestone value distribution, US$million - marketed stage
Figure 36: Bioinformatics deals with royalty rates- by stage of development
Figure 37: Bioinformatics deal royalty rates value distribution, US$million - discovery stage
Figure 38: Bioinformatics deal royalty rates value distribution, US$million - preclinical stage
Figure 39: Bioinformatics deal royalty rates value distribution, US$million - phase I stage
Figure 40: Bioinformatics deal royalty rates value distribution, US$million - phase II stage
Figure 41: Bioinformatics deal royalty rates value distribution, US$million - phase III stage
Figure 42: Bioinformatics deal royalty rates value distribution, US$million - regulatory stage
Figure 43: Bioinformatics deal royalty rates value distribution, US$million - marketed stage
Figure 44: Summary median milestone value by stage of development, 2007-2013
Figure 45: Top bioinformatics deals by value since 2007
Figure 46: Top bioinformatics deals signed by big pharma value since 2007
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events



Companies mentioned

Abbott Japan

Abbott Laboratories

Abraxis BioScience

ACADIA Pharmaceuticals

Acceleron Pharma

Achillion Pharmaceuticals

Adnexus Therapeutics

Adolor

AEterna Zentaris

Affymax

Agensys

Alfacell

Allergan

Ambit Biosciences

Amgen

Amylin Pharmaceuticals

Anacor Pharmaceuticals

Anesiva

Archemix

Ariad Pharmaceuticals

ArQule

Array Biopharma

ARYx Therapeutics

Astellas Pharma

AstraZeneca

Athersys

Atley Pharmaceuticals

Auriga Laboratories

Aventis

AVEO Pharmaceuticals

Barrier Therapeutics

Bayer

Biogen Idec

BioMarin Pharmaceuticals

BioMerieux

Biovail

Boehringer Ingelheim

Bristol-Myers Squibb

Cardiome Pharma

Celgene

Cell Genesys

Cepheid

ChemoCentryx

Cornerstone Biopharma

Cortex Pharmaceuticals

Critical Therapeutics

Cubist Pharmaceuticals

CV Therapeutics

Cypress Bioscience

Cytokinetics

Daiichi Sankyo

DepoMed

Dey Pharma

DoctorDirectory

DOR BioPharma

Dyax

Dynavax Technologies

Eisai

Eli Lilly

Enanta Pharmaceuticals

Endo Pharmaceuticals

Exelixis

Facet Biotechnology

Forest Laboratories

Forest Pharmaceuticals

Galderma

Genentech

Genzyme

Gilead Sciences

GlaxoSmithKline

GTx

Hyperion Therapeutics

ImmunoGen

Immunomedics

Impax Laboratories

Incyte

Inspire Pharmaceuticals

InterMune

InVentiv Health

Ipsen

Ironwood Pharmaceuticals

Janssen Research and Development

KaloBios Pharmaceuticals

La Jolla Pharmaceutical

Macrogenics

MAP Pharmaceuticals

Maxygen

Medivation

Menarini

Merck and Co

Merck KGaA

Merck Sharpe and Dohme

Merrimack Pharmaceuticals

Metabasis Therapeutics

Micromet

MiddleBrook Pharmaceutical

Millennium

Mylan Laboratories

Nektar Therapeutics

Novartis

Novartis Consumer Health

Novo Nordisk

Nycomed

OncoGenex Pharmaceuticals

Optimer Pharmaceuticals

Orexigen Therapeutics

Ortho Biotech

Par Pharmaceutical

PDL BioPharma

Pfizer

PhotoMedex

Procter and Gamble

Procter and Gamble Pharmaceuticals

Purdue Pharma

Regeneron Pharmaceuticals

Rib-X Pharmaceuticals

Roche

Sagent Pharmaceuticals

Salix Pharmaceuticals

Sanofi-Aventis

Sanofi-Pasteur

Sanofi

Santarus

Schering-Plough

Seattle Genetics

Serono

Sigma-Tau

Solvay

Somaxon Pharmaceuticals

Spectrum Pharmaceuticals

Strativa Pharmaceuticals

Sucampo Pharmaceuticals

Synta Pharmaceuticals

Takeda Pharmaceutical

TAP Pharmaceutical

Targacept

Tercica

Teva Pharmaceuticals

Tibotec

Transcept Pharmaceuticals

Ucyclyd Pharma

Valeant Pharmaceuticals

Veracyte

Vernalis

Vical

Victory Pharma

Warner Chilcott

Watson Pharmaceuticals

Wyeth

Xenoport

Zogenix

ZymoGenetics

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Next-generation Sequencing Market

Global Next-generation Sequencing Market

  • $ 10 000
  • Industry report
  • June 2014
  • by Frost & Sullivan

On the Verge of a Quadrupled Competitor Size and a Clinical Turning Point The total market, as defined by this study, includes next-generation sequencing instruments and reagents. Instruments include those ...

Sample Preparation Market by Product [Instruments (Workstations, Liquid Handling Systems), Consumables (Tubes), Kits (Isolation, Purification)], Application (Genomics, Proteomics) & by End Users (Molecular Diagnostics) - Global Forecast to 2018

Sample Preparation Market by Product [Instruments (Workstations, Liquid Handling Systems), Consumables (Tubes), Kits (Isolation, Purification)], Application (Genomics, Proteomics) & by End Users (Molecular Diagnostics) - Global Forecast to 2018

  • $ 4 650
  • Industry report
  • May 2014
  • by MarketsandMarkets

Over the years, the sample preparation market, comprising of instruments, consumables, accessories and kits, has witnessed various technological advancements. These advancements have led to a growth in ...

Metabolomics Market by Technique, Application & by Indication - Global Forecast to 2019

Metabolomics Market by Technique, Application & by Indication - Global Forecast to 2019

  • $ 4 650
  • Industry report
  • June 2014
  • by MarketsandMarkets

In this report, the global metabolomics market is segmented based on techniques, applications, indications, and geography. Based on techniques, the metabolomics market is classified into Gas Chromatography, ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.